Johnson & Johnson (JNJ) looks undervalued with the market likely but not fully appreciating the broad innovation across the firm’s pipeline, notes Morningstar’s Damien Conover. He and Third Bridge’s Lee Brown discuss JNJ’s earnings. Brown suggests that JNJ’s top line performance was driven by the company innovative medicine segment.